1 | – in a costeffective | | | | | | | 2 | 0.54% |
2 | adherence confers a significant | | | | | | | 1 | 0.27% |
3 | pipeline takes aim at | | | | | | | 1 | 0.27% |
4 | adverse outcomes” the cardiopharma | | | | | | | 1 | 0.27% |
5 | subsequent adverse outcomes” the | | | | | | | 1 | 0.27% |
6 | with subsequent adverse outcomes” | | | | | | | 1 | 0.27% |
7 | association with subsequent adverse | | | | | | | 1 | 0.27% |
8 | confers a significant inverse | | | | | | | 1 | 0.27% |
9 | cardiopharma home about us | | | | | | | 1 | 0.27% |
10 | aim at significant medical | | | | | | | 1 | 0.27% |
11 | optimal adherence confers a | | | | | | | 1 | 0.27% |
12 | of optimal adherence confers | | | | | | | 1 | 0.27% |
13 | level of optimal adherence | | | | | | | 1 | 0.27% |
14 | the level of optimal | | | | | | | 1 | 0.27% |
15 | medications alone and that | | | | | | | 1 | 0.27% |
16 | vascular medications alone and | | | | | | | 1 | 0.27% |
17 | to vascular medications alone | | | | | | | 1 | 0.27% |
18 | takes aim at significant | | | | | | | 1 | 0.27% |
19 | significant medical needs – | | | | | | | 1 | 0.27% |
20 | at significant medical needs | | | | | | | 1 | 0.27% |
21 | and payers around the | | | | | | | 1 | 0.27% |
22 | is dedicated to developing | | | | | | | 1 | 0.27% |
23 | cardiopharma is dedicated to | | | | | | | 1 | 0.27% |
24 | of cardiopharma is dedicated | | | | | | | 1 | 0.27% |
25 | pipeline of cardiopharma is | | | | | | | 1 | 0.27% |
26 | the pipeline of cardiopharma | | | | | | | 1 | 0.27% |
27 | world the pipeline of | | | | | | | 1 | 0.27% |
28 | pharmacists and payers around | | | | | | | 1 | 0.27% |
29 | poor adherence to vascular | | | | | | | 1 | 0.27% |
30 | providers pharmacists and payers | | | | | | | 1 | 0.27% |
31 | patients providers pharmacists and | | | | | | | 1 | 0.27% |
32 | for patients providers pharmacists | | | | | | | 1 | 0.27% |
33 | – for patients providers | | | | | | | 1 | 0.27% |
34 | manner – for patients | | | | | | | 1 | 0.27% |
35 | needs – in a | | | | | | | 1 | 0.27% |
36 | medical needs – in | | | | | | | 1 | 0.27% |
37 | adherence to vascular medications | | | | | | | 1 | 0.27% |
38 | to poor adherence to | | | | | | | 1 | 0.27% |
39 | products which provide improved | | | | | | | 1 | 0.27% |
40 | should 2 there continues | | | | | | | 1 | 0.27% |